Follow our progress.

Milestones in our journey to reinvent genetic testing.

View full list

Press Releases

Invitae Announces Third Quarter 2016 Financial Results, Secures Contracts with Top Five Largest Payers, and Grows Volume More Than 200% Year-Over-Year

Invitae Announces Third Quarter 2016 Financial Results, Secures Contracts with Top Five Largest Payers, and Grows Volume More Than 200% Year-Over-Year

November 07, 2016

Lives covered now at more than 160,000,000

Reduced COGS to $450 per sample, expects to be cash flow positive by end of 2018

Hosting webinar/conference call at 4:45 pm ET / 1:45 pm PT

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the third quarter ended September 30, 2016. Year to date, the company has secured contracts with the top five major payers while making substantial progress on all four of its key metrics. The company also stated it expects to be cash flow positive by the end of 2018.

“We believe Invitae has emerged from being a concept story to a company that has industry-leading growth rates in the genetic testing market with a clear path to becoming cash flow positive,” said Randy Scott, chairman and chief executive officer at Invitae. “With our recently announced progress in contracting with the top five major payers, we are now shifting our emphasis to driving revenue as a top priority.  We will be working diligently to begin to operationalize those contracts as we move in network which should significantly improve our payment rates and drive volume growth throughout 2017 and beyond.”

The company reported total revenue of $6.3 million in the third quarter of 2016, compared to $2.2 million in the third quarter of 2015. Total costs and operating expenses were $31.2 million in the third quarter of 2016 compared to $24.6 million for the third quarter of 2015. Cost of revenue (cost of tests delivered) was $7.2 million for approximately 15,500 samples accessioned in the third quarter of 2016 compared to $4.0 million for more than 5,400 samples accessioned in the third quarter of 2015.

Operating expenses, excluding cost of revenue (cost of tests delivered), were $23.9 million in the third quarter of 2016 compared to $20.7 million for the third quarter of 2015. Net loss was $25.0 million in the third quarter of 2016, or a $0.77 loss per share, compared to $22.5 million in the third quarter of 2015, or a $0.71 loss per share. Operating expenses in the third quarter of 2016 included non-cash expenses of approximately $5.3 million, including depreciation, equity compensation, and non-cash rent expense for a new production facility, which the company expects to occupy later this year.

At September 30, 2016, cash, cash equivalents, restricted cash, and marketable securities totaled approximately $71.4 million, approximately $18.8 million less than the comparable amount as of June 30, 2016.

“This quarter represents a turning point for us as we believe we have substantially reduced the technical, market, and execution risk against our business plan and have a runway to ramp our revenue and create a profitable long-term business,” said Sean George, president and chief operating officer at Invitae. “Over the past two years, you’ve seen us emerge from a concept – bringing genetics into mainstream medicine – into a rapidly growing business with a clear path to positive cash flow.”

The following are recent highlights:

  • Increased volume: Increased volume by 200% year-over-year and 25% quarter-over-quarter by delivering approximately 15,200 billable reports and accessioning approximately 15,500 samples.
  • Lowered COGS: Reduced cost of goods sold per sample accessioned (COGS) from approximately $500 in the second quarter of 2016 to approximately $450 in the third quarter of 2016.
  • Expanded content: Introduced expanded neurology and cardiology test offerings, including new panels for Parkinson’s disease, neuropathies, neuromuscular diseases, and a cardiomyopathy and skeletal muscle disease panel, and added new genes to panels for arrhythmias, cardiomyopathies, aortopathies, and congenital heart disease.
  • Improved reimbursement: Established reimbursement with the top five national payers, bringing total lives covered to more than 160 million, up from approximately 95 million in the second quarter of 2016. In addition, announced Medicare and Medicaid Services’ (CMS) final pricing of $925 for genetic testing for hereditary breast cancer-related disorders (e.g. hereditary breast cancer, hereditary ovarian cancer, and hereditary endometrial cancer).
  • Secured new collaborator for Invitae’s Genome Network: Announced a collaboration with Helix to build some of the first proactive health apps for healthy individuals in the Helix marketplace for common, actionable inherited disorders for which there are preventive measures available. The collaboration will initially focus on common, actionable genes associated with inherited forms of cancer and cardiovascular disease, with plans to offer additional applications in the future. This adds to Invitae’s growing network of biopharma, platform, researcher, and patient advocacy collaborators.
  • Contributed data on an array of topics in genetics: Presented multiple abstracts at medical meetings:

Webinar and Conference Call Details
Management will host a webinar and conference call at 4:45 pm ET / 1:45 pm PT. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 5259406.

The live webcast of the conference call may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website.

About Invitae
Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas. For more information, visit our website at invitae.com.

Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s beliefs regarding its positioning in the market;  the company’s expectations regarding being cash flow positive; future performance levels; the indicators of the company’s success and its expected actions with respect to those indicators; the company’s belief that it has industry-leading market share and growth rates; the company’s prioritization of driving revenue; the company’s expectation that it will begin to operationalize contracts with major payers, and that payment rates and volume will increase throughout 2017 and beyond; the company’s belief that it has substantially reduced risk, and has a runway to ramp revenue and create a profitable long-term business; the ultimate functionality, features, availability and processes used by the Invitae apps and the Helix marketplace; and the company’s beliefs with respect to the benefits of the Invitae apps and the Helix marketplace. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the company’s ability to develop and commercialize new tests and expand into new markets; the company’s ability to use rapidly changing genetic data to interpret test results accurately, consistently and quickly; the company’s history of losses; the company’s need to scale its infrastructure in advance of demand for its tests and its ability to increase demand for its tests; the company’s ability to drive revenue as a top priority; the company’s ability to successfully operationalize payer contracts; the company’s ability to achieve and maintain positive cash flows and to execute its strategy to create a profitable long term business; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; laws and regulations applicable to the company’s business, including potential regulation by the Food and Drug Administration; that Medicare may change the pricing or other terms for reimbursement, or not reimburse the company for other tests in the future; the risk that the company’s apps on the Helix platform are not ultimately launched; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are the property of their respective owners. 

Source: Invitae Corporation

Contact:
Laura D’Angelo
pr@invitae.com
314-920-0617 

 

Share

Return to press releases